Photo by kilyan_s from unsplash
Cardiologists in India have warned that the government’s uniform price cap on coronary stents may keep the latest models out of the Indian market and compromise safety during percutaneous coronary… Click to show full abstract
Cardiologists in India have warned that the government’s uniform price cap on coronary stents may keep the latest models out of the Indian market and compromise safety during percutaneous coronary interventions in patients with complex arterial disease. India’s National Pharmaceutical Pricing Authority (NPPA), the government agency that regulates prices, had in February this year imposed a price cap of INR30 000 (£360; €427; $464) on all drug eluting stents, some of which had previously been available to patients at prices of over INR180 000. This is the first time that the government has put a coronary device on the national list of essential medicines, allowing it to be subject to price control. The NPPA had last year described India’s market for coronary stents …
Journal Title: British Medical Journal
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!